Healthcare -
Biotechnology - NASDAQ - US
$ 0.6848
-10.7 %
$ 2.48 M
Market Cap
-0.06
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
ZyVersa Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 9.13 M |
| Operating Income | -9.14 B |
| Other Expenses | -9.13 B |
| Net Income | -9.41 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|---|
| REVENUE | |||||
| Revenue | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||
| Cost Of Revenue | 0 | 10.4 K | 10.4 K | 10.4 K | 10.4 K |
| Gross Profit | 0 | 10.4 K | 10.4 K | 10.4 K | 10.4 K |
| OPERATING INCOME | |||||
| Operating Expenses | 9.1 | 14.4 | 13.0 | 7.7 | 11.8 |
| Selling, General and Administrative Expenses | 7 357.6 | 11.2 | 7.6 | 5.6 | 5.4 |
| Research and Development Expenses | 1 779.3 | 3.2 | 5.4 | 2.1 | 6.5 |
| Operating Income | (9 136.8) | (14.4) | (13.0) | (7.7) | (11.8) |
| PRE-TAX INCOME | |||||
| Interest Income Expense | 0.3 | (0.5) | 0.4 | 0.8 | 0.5 |
| Total Other Income | (283.3) | (93.3) | (2.4) | (0.4) | (0.9) |
| Pre-Tax Income | (9 420.2) | (107.8) | (14.0) | (8.1) | (12.7) |
| NET INCOME | |||||
| Tax Provision | (6.7) | (9.5) | 745.0 | 0.8 | 0.5 |
| Net Income | (9 413.4) | (98.3) | (759.1) | (8.9) | (13.2) |
| EPS | 848 | 1.09 K | 930 | 174 | 272 |